Legend Biotech Corp (LEGN)

Legend Biotech is a biopharmaceutical company that makes cell therapies—medicines that take a patient’s own immune cells, reprogram them in a laboratory, and return them to fight cancer. The most advanced therapy, ciltacabtagene autoleucel (cilta-cel), targets blood cancers, and the company is also exploring whether the same technology can work against solid tumors. Unlike traditional drugs manufactured in large batches, cell therapies are personalized: each patient’s cells are engineered individually, making the business model and manufacturing fundamentally different from conventional pharma.

What a CAR-T cell therapy is, in plain terms

A typical cancer drug enters the bloodstream, circulates through the body, and hopes to find and kill cancer cells before the body’s filters clear it out. CAR-T is different. A CAR-T therapy starts by drawing blood from the patient. Technicians isolate T cells—the immune cells that patrol for infection and disease—and then edit them in a lab using genetic engineering. They add instructions that teach the T cells to recognize a specific protein on the surface of cancer cells. The edited cells are grown in number—sometimes millions of them—and then returned to the patient, where they circulate and hunt down any cell carrying that cancer marker.

The advantage is specificity. Once a T cell has the right targeting instructions, it does not forget them. If a cancer cell is hiding somewhere in the body, the engineered T cell will find it. And because the therapy is made from the patient’s own cells, there is no foreign-body rejection the way there would be with a transplant. The cell itself becomes the medicine, multiplying and persisting for years after a single infusion.

The challenge is complexity. Because each dose is manufactured for one specific patient, scaling up means building the infrastructure to make thousands of individualized medicines. There are no warehouses of generic CAR-T cells. And because cells are living organisms, every batch behaves slightly differently. The manufacturing process is labour-intensive, time-sensitive, and expensive per patient.

Legend’s journey and cilta-cel

Legend Biotech was founded in Shanghai in 2008 and initially worked on CAR-T therapies in academic collaboration with Chinese institutions. The company’s lead program, cilta-cel, targets a protein called B-cell maturation antigen, or BCMA, which sits on the surface of multiple myeloma cells (a blood cancer of bone marrow) and certain types of lymphoma. After years of clinical testing, cilta-cel showed the ability to shrink advanced myeloma in a majority of patients, including many who had run out of other options. That clinical record—the data showing durable remissions in otherwise-doomed patients—became the foundation for regulatory approval.

In 2020, Legend partnered with Janssen (the pharmaceutical division of Johnson & Johnson), which had the scale, regulatory relationships, and commercial infrastructure to bring a cell therapy to market globally. Under the deal, Janssen gained rights to cilta-cel outside of China, while Legend retains rights in the Chinese market and continues to develop the therapy. Janssen’s involvement brought both capital and credibility; a small Chinese biotech alone would struggle to win trust from American and European regulators and hospitals.

Cilta-cel received regulatory approval in the United States and Europe for multiple myeloma. This was significant because myeloma patients who have exhausted conventional treatments—there are now many options—face a grim prognosis, and a therapy that can deliver years of remission to a large fraction of them fills a genuine unmet need.

How the economics actually work

A traditional drug company manufactures a pill or injection in large batches, then sells millions of doses. Profit comes from volume and price. A CAR-T cell therapy company manufactures one personalized dose per patient. The revenue model inverts: instead of cost-per-unit declining sharply as volume climbs, manufacturing stays labour-intensive and therefore expensive per dose, no matter the total volume. This means cell therapies command premium prices—a single course of treatment can cost hundreds of thousands of dollars—and that in turn means the addressable market is only patients with advanced disease who can access the healthcare system and afford the price.

Legend does not manufacture cilta-cel itself—the actual production happens at manufacturing sites run by partners. The company receives revenue sharing or milestone payments from Janssen based on sales in licensed territories, while manufacturing and distribution in China are handled separately. This model reduces Legend’s capital requirements (it does not need to build and operate vast manufacturing plants) but also means the company captures a smaller percentage of each dose sold.

Profitability in cell therapy is not straightforward. Early revenues go largely toward funding the R&D required to expand the therapy to new indications and to build internal capability. Legend is still investing heavily in developing new CAR-T programs and exploring whether the same technology can work against solid tumors—a far larger market than blood cancers, but technically much harder. That R&D spending depresses near-term profits even as revenue grows.

The science that makes it hard to copy

CAR-T therapy sounds simple in concept: edit the cell, grow it, return it. In practice, the engineering is intricate. How do you minimize the risk that T cells attack healthy tissue as well as cancer? How do you engineer them to persist long-term, multiplying and remembering the target for years? How do you manufacture a living product consistently, scaling from dozens of patient doses to thousands without losing efficacy?

Legend’s intellectual property—the specific CAR designs, the manufacturing methods, the refinements that make cilta-cel work as well as it does—represents years of R&D and creates genuine barriers to competition. But the field of CAR-T is not a Legend monopoly. Other companies, including Novartis and Bristol Myers Squibb, have their own approved CAR-T therapies. Competition is real, and as the field matures, price pressure is likely. The differentiation comes down to clinical performance, manufacturing reliability, and the breadth of indications a company can reach.

Solid tumours: the frontier and the gamble

The initial success of CAR-T in blood cancers created an obvious next question: can the same trick work against solid tumors—lung cancer, ovarian cancer, pancreatic cancer? The market for effective solid-tumor therapies is enormous. But the biology is far harder. Solid tumors are heterogeneous, often surrounded by an immunosuppressive microenvironment, and lack a single shared target the way blood cancers have BCMA. Many companies have tried and failed to make CAR-T work in solid tumors; the early clinical data are mixed.

Legend is pursuing multiple solid-tumor targets, betting that one or more will bear fruit. Success in even one indication would transform the company’s scale and addressable market. But that is still a gamble, and much of Legend’s longer-term value lies in that bet.

How to understand Legend as an investment

Start with the company’s clinical data: what has cilta-cel shown in myeloma and lymphoma, and are those results being borne out in real-world use? The 10-K (SEC CIK 0001801198) details the partnership with Janssen, including how revenue is recognized and what milestones Legend can still earn. Watch the quarterly earnings calls for updates on solid-tumor programs, manufacturing scale, and the health of the Chinese market—a large opportunity for cilta-cel that faces different regulatory and pricing dynamics from the United States.

Key questions: Are the sales numbers meeting company guidance, or is there market adoption lag? Is the manufacturing process becoming more reliable and efficient? And what is the strength of the solid-tumor pipeline—are early data encouraging or discouraging? CAR-T therapy is not speculative science anymore; cilta-cel is a proven treatment. But Legend’s future depends on whether it can broaden the indications, improve manufacturing, and survive the inevitable price competition that follows successful drugs across the industry.